Pfizer Inc. (NYSE:PFE)‘s stock had its “neutral” rating reaffirmed by equities researchers at Societe Generale in a report released on Thursday. They presently have a $36.00 price target on the biopharmaceutical company’s stock. Societe Generale’s price target suggests a potential upside of 5.88% from the company’s current price.
Several other brokerages have also recently weighed in on PFE. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research report on Tuesday, December 20th. Sanford C. Bernstein reaffirmed an “overweight” rating on shares of Pfizer in a research report on Wednesday, December 7th. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $34.97 price target on the stock. in a research report on Thursday, February 23rd. Piper Jaffray Companies set a $53.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Saturday, January 21st. Finally, Barclays PLC set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday, March 16th. Thirteen equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $37.42.
Pfizer (NYSE:PFE) opened at 34.00 on Thursday. Pfizer has a 52-week low of $29.41 and a 52-week high of $37.39. The stock has a 50 day moving average price of $33.72 and a 200 day moving average price of $32.84. The firm has a market cap of $202.36 billion, a P/E ratio of 28.99 and a beta of 0.94.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $0.47 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.50 by $0.03. Pfizer had a net margin of 13.50% and a return on equity of 23.18%. The business earned $13.60 billion during the quarter, compared to the consensus estimate of $13.64 billion. During the same period in the previous year, the business posted $0.53 EPS. Pfizer’s revenue was down 3.0% compared to the same quarter last year. Equities analysts predict that Pfizer will post $2.55 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Mideast Time and is the sole property of of Mideast Time. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.mideasttime.com/pfizer-inc-pfe-rating-reiterated-by-societe-generale/1588852.html.
In related news, insider Charles H. Hill sold 36,000 shares of Pfizer stock in a transaction that occurred on Thursday, March 9th. The shares were sold at an average price of $34.07, for a total value of $1,226,520.00. Following the sale, the insider now owns 57,329 shares of the company’s stock, valued at approximately $1,953,199.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rady A. Johnson sold 4,500 shares of Pfizer stock in a transaction that occurred on Friday, March 10th. The stock was sold at an average price of $34.19, for a total transaction of $153,855.00. Following the completion of the sale, the insider now directly owns 54,963 shares in the company, valued at approximately $1,879,184.97. The disclosure for this sale can be found here. Insiders sold a total of 71,470 shares of company stock worth $2,449,150 in the last ninety days. 0.07% of the stock is currently owned by insiders.
Several large investors have recently bought and sold shares of the company. First American Bank boosted its stake in Pfizer by 8.2% in the third quarter. First American Bank now owns 172,063 shares of the biopharmaceutical company’s stock worth $5,827,000 after buying an additional 13,071 shares during the period. Independence Advisors LLC boosted its stake in Pfizer by 5.7% in the third quarter. Independence Advisors LLC now owns 74,838 shares of the biopharmaceutical company’s stock worth $2,535,000 after buying an additional 4,051 shares during the period. Liberty Capital Management Inc. boosted its stake in Pfizer by 8.0% in the third quarter. Liberty Capital Management Inc. now owns 12,254 shares of the biopharmaceutical company’s stock worth $413,000 after buying an additional 910 shares during the period. Foundry Partners LLC boosted its stake in Pfizer by 10.5% in the third quarter. Foundry Partners LLC now owns 890,380 shares of the biopharmaceutical company’s stock worth $30,157,000 after buying an additional 84,675 shares during the period. Finally, Baystate Wealth Management LLC boosted its stake in Pfizer by 6.2% in the third quarter. Baystate Wealth Management LLC now owns 29,901 shares of the biopharmaceutical company’s stock worth $1,013,000 after buying an additional 1,747 shares during the period. 69.53% of the stock is currently owned by institutional investors.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.